公开(公告)号：EP1423115B9

公开(公告)日：2009-09-02

申请号：EP02757019.1

申请日：2002-08-06

申请人： The Children's Medical Center Corporation ,  EntreMed, Inc.

发明人： SHAH, Jamshed, H. ,  CONNER, Barry, P. ,  SWARTZ, Glenn., M., Jr. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  D'AMATO, Robert ,  PRIBLUDA, Victor ,  TRESTON, Anthony

IPC分类号： A61K31/454 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07D401/04 ,  A61K31/454

摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substitutued thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

公开(公告)号：EP1423115B1

公开(公告)日：2009-04-15

申请号：EP02757019.1

申请日：2002-08-06

申请人： The Children's Medical Center Corporation ,  EntreMed, Inc.

发明人： SHAH, Jamshed, H. ,  CONNER, Barry, P. ,  SWARTZ, Glenn., M., Jr. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  D'AMATO, Robert ,  PRIBLUDA, Victor ,  TRESTON, Anthony

IPC分类号： A61K31/454 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07D401/04 ,  A61K31/454

摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substitutued thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

摘要翻译： 本发明包含有效抑制血管生成的一组化合物。 更具体地说，氮取代的沙利度胺类似物和二取代的沙利度胺类似物已被证明可抑制血管生成。 重要的是，这些化合物可以口服给药。

公开(公告)号：EP1423115A2

公开(公告)日：2004-06-02

申请号：EP02757019.1

申请日：2002-08-06

申请人： The Children's Medical Center Corporation ,  EntreMed, Inc.

发明人： SHAH, Jamshed, H. ,  CONNER, Barry, P. ,  SWARTZ, Glenn., M., Jr. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  D'AMATO, Robert ,  PRIBLUDA, Victor ,  TRESTON, Anthony

IPC分类号： A61K31/454

CPC分类号： C07D401/04 ,  A61K31/454

摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substitutued thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

公开(公告)号：EP1353672A2

公开(公告)日：2003-10-22

申请号：EP01270117.3

申请日：2001-11-30

申请人： The Children's Medical Center Corporation

发明人： TRESTON, Anthony ,  SHAH, Jamshed, H. ,  D'AMATO, Robert, J. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  CONNER, Barry, P. ,  PRIBLUDA, Victor ,  SWARTZ, Glenn, M.

IPC分类号： A61K31/445

CPC分类号： C07D401/04 ,  A61K31/454 ,  Y02A50/401

摘要： Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.

公开(公告)号：EP1353672B1

公开(公告)日：2007-10-03

申请号：EP01270117.3

申请日：2001-11-30

申请人： The Children's Medical Center Corporation

发明人： TRESTON, Anthony ,  SHAH, Jamshed, H. ,  D'AMATO, Robert, J. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  CONNER, Barry, P. ,  PRIBLUDA, Victor ,  SWARTZ, Glenn, M.

IPC分类号： A61K31/445 ,  C07D401/04

CPC分类号： C07D401/04 ,  A61K31/454 ,  Y02A50/401

摘要： Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.

公开(公告)号：EP1778652A2

公开(公告)日：2007-05-02

申请号：EP05791547.2

申请日：2005-08-19

申请人： EntreMed, Inc.

发明人： AGOSTON, Gregory, E. ,  HEMBROUGH, Todd, A. ,  LAVALLEE, Theresa, M. ,  SHAH, Jamshed, H. ,  SUWANDI, Lita ,  TRESTON, Anthony, M.

IPC分类号： C07D261/18 ,  C07D235/30 ,  C07D403/02

CPC分类号： C07D295/185 ,  C07D205/04 ,  C07D207/34 ,  C07D213/56 ,  C07D213/82 ,  C07D231/40 ,  C07D233/64 ,  C07D235/26 ,  C07D235/30 ,  C07D241/26 ,  C07D249/04 ,  C07D261/18 ,  C07D275/03 ,  C07D277/46 ,  C07D403/06 ,  C07D487/04

摘要： Compositions and methods comprising proteinase activated receptor antagonists are provided. More particularly, the present invention relates to the use of proteins, peptides and molecules that bind to proteinase activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.

公开(公告)号：EP1756139A2

公开(公告)日：2007-02-28

申请号：EP05736385.5

申请日：2005-03-11

申请人： EntreMed, Inc. ,  Agoston, Gregory E. ,  Shah, Jamshed, H.

发明人： AGOSTON, Gregory, E. ,  SHAH, Jamshed, H. ,  SUWANDI, Lita ,  LAVALLEE, Theresa, M. ,  TRESTON, Anthony

IPC分类号： C07J1/00 ,  C07J11/00 ,  A61K31/56

CPC分类号： C07J1/00

摘要： Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formula I (I), or formula II (II), wherein Ra is selected from -OCH3, OCH2CH3 or -CCCH3; and Z is selected from >C(H)-OH, >C(H)-O-alkyl, >C(H)-O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.

公开(公告)号：EP1206480A2

公开(公告)日：2002-05-22

申请号：EP00964915.3

申请日：2000-08-23

申请人： EntreMed, Inc.

发明人： AGOSTON, Gregory, E. ,  TRESTON, Anthony, M. ,  SHAH, Jamshed, H.

IPC分类号： C07J1/00

CPC分类号： C07J1/007

摘要： 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.

摘要翻译： 通过合成或纯化方法获得纯度大于98％的2-甲氧基雌二醇。 这种高纯度的2-甲氧基雌二醇缺乏雌激素成分，特别适用于人体临床应用。 本发明的纯化方法涉及使用液 - 固色谱（LSC）将2-ME2与其他化合物分离。 色谱介质优选为二氧化硅。 溶剂体系包含非极性溶剂（如氯仿）和极性溶剂（如甲醇）。

公开(公告)号：EP1633367A2

公开(公告)日：2006-03-15

申请号：EP04809420.5

申请日：2004-05-28

申请人： EntreMed, Inc.

发明人： AGOSTON, Gregory, E ,  LAVALLEE, Theresa, M. ,  PRIBLUDA, Victor, S. ,  SHAH, Jamshed, H. ,  TRESTON, Anthony, M.

IPC分类号： A61K31/56 ,  C07J1/00 ,  C07J3/00 ,  C07J7/00 ,  C07J31/00 ,  C07J41/00

CPC分类号： C07J41/00

摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.

公开(公告)号：EP1343803A2

公开(公告)日：2003-09-17

申请号：EP01968112.1

申请日：2001-08-24

申请人： EntreMed, Inc.

发明人： AGOSTON, Gregory ,  SHAH, Jamshed, H. ,  HUNSUCKER, Kimberly, A. ,  PRIBLUDA, Victor ,  LAVALLEE, Theresa, M. ,  GREEN, Shawn, J. ,  HERBSTRITT, Christopher, J. ,  ZHAN, Xiaoguo, H. ,  TRESTON, Anthony

IPC分类号： C07J1/00 ,  C07J13/00 ,  C07J41/00 ,  C07J9/00 ,  C07J3/00 ,  C07J7/00 ,  A61K31/56 ,  A61P35/00

CPC分类号： C07J1/00

摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.